Deal Library / Pharma BD Deal Intelligence

Oncology Deals

The Pharma Closeout tracks 268 deals, $700.5B in disclosed deal value, 156 with a post-close Outcome Score for Oncology.

Median Critic Score: 80  ·  Median Outcome Score: 62

Best outcome: AstraZeneca PLC / Daiichi Sankyo Company, Limited (100)  ·  Weakest outcome: AbbVie Inc. / Stemcentrx Inc. (9)

All 268 deals

• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2019 · $6.9B · Worked — the deal delivered on its rationale.
• Novartis AG / Endocyte, Inc. — 2018 · $2.1B · Worked — the deal delivered on its rationale.
• Astellas Pharma Inc. / Seagen Inc. — 2009 · $4.5B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Medarex Inc. — 2009 · $2.4B · Worked — the deal delivered on its rationale.
• Servier / Agios Pharmaceuticals (oncology) — 2020 · $2.0B · Worked — the deal delivered on its rationale.
• Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. — 2020 · $2.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Aragon Pharmaceuticals Inc. — 2013 · $1.0B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Loxo Oncology, Inc. — 2019 · $8.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Peloton Therapeutics Inc. — 2019 · $2.2B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / AstraZeneca PLC — 2017 · $8.5B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2015 · $1.1B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2022 · $250M · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Medivation Inc. — 2016 · $14.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Acerta Pharma — 2015 · $4.0B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2018 · $5.3B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2016 · $250M · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2018 · $5.8B · Worked — the deal delivered on its rationale.
• Celgene Corporation / Agios Pharmaceuticals Inc. — 2010 · $130M · Worked — the deal delivered on its rationale.
• American Home Products Corporation / American Cyanamid Company — 1994 · $9.7B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Genmab A/S — 2020 · $3.9B · Worked — the deal delivered on its rationale.
• Exact Sciences Corporation / Genomic Health, Inc. — 2019 · $2.8B · Worked — the deal delivered on its rationale.
• Astellas Pharma Inc. / Ganymed Pharmaceuticals — 2016 · $1.4B · Worked — the deal delivered on its rationale.
• Novartis AG / GlaxoSmithKline plc — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• Ipsen S.A. / Exelixis Inc. — 2016 · $855M · Worked — the deal delivered on its rationale.
• Summit Therapeutics plc / Akeso Inc. — 2023 · $4.5B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Tesaro Inc. — 2018 · $5.1B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Genentech, Inc. (Roche Group) — 2007 · Worked — the deal delivered on its rationale.
• Amgen Inc. / Five Prime Therapeutics — 2021 · $1.9B · Worked — the deal delivered on its rationale.
• Boston Scientific Corporation / BTG plc — 2018 · $4.2B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Seagen Inc. — 2023 · $43.0B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Arvinas, Inc. — 2021 · $2.4B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Genmab A/S — 2012 · $3.0B · Worked — the deal delivered on its rationale.
• Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals — 2003 · $5.2B · Worked — the deal delivered on its rationale.
• Sanofi SA / Amunix Pharmaceuticals Inc. — 2021 · $1.2B · Worked — the deal delivered on its rationale.
• GSK plc / Novartis AG — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. — 2011 · Worked — the deal delivered on its rationale.
• Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. — 2026 · $2.5B · Worked — the deal delivered on its rationale.
• GSK plc / Hansoh Pharmaceutical Group Co. Ltd. — 2023 · $1.7B · Largely worked — most objectives met.
• Merck & Co. Inc. / Bristol-Myers Squibb Company — 2017 · $625M · Largely worked — most objectives met.
• AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd — 2026 · $1.5B · Largely worked — most objectives met.
• Roche Holding AG / Ignyta Inc. — 2017 · $1.7B · Largely worked — most objectives met.
• Merck KGaA / SpringWorks Therapeutics — 2025 · $3.4B · Largely worked — most objectives met.
• Pfizer Inc. / Array BioPharma Inc. — 2019 · $11.4B · Largely worked — most objectives met.
• Pfizer Inc. / Innovent Biologics, Inc. — 2026 · $10.5B · Largely worked — most objectives met.
• Novartis AG / PeptiDream Inc. — 2024 · $2.9B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / SystImmune Inc. — 2023 · $8.4B · Largely worked — most objectives met.
• GSK plc / Nuvalent, Inc. — 2026 · $10.6B · Largely worked — most objectives met.
• AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. — 2025 · $2.0B · Largely worked — most objectives met.
• GSK plc / Sierra Oncology Inc. — 2022 · $1.9B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. — 2022 · $4.1B · Largely worked — most objectives met.
• Johnson & Johnson / ALZA Corporation — 2001 · $10.5B · Largely worked — most objectives met.
• Ono Pharmaceutical Co., Ltd. / Deciphera Pharmaceuticals — 2024 · $2.4B · Largely worked — most objectives met.
• AbbVie Inc. / ImmunoGen Inc. — 2023 · $10.1B · Largely worked — most objectives met.
• Ipsen S.A. / Kartos Therapeutics, Inc. — 2026 · $1.8B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / RayzeBio Inc. — 2023 · $4.1B · Largely worked — most objectives met.
• Merck & Co. Inc. / Daiichi Sankyo Company, Limited — 2023 · $22.0B · Largely worked — most objectives met.
• Amgen Inc. / BeiGene Ltd. — 2020 · $2.8B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Immunomedics Inc. — 2020 · $21.0B · Largely worked — most objectives met.
• GSK plc / Bellus Health Inc. — 2003 · $2.0B · Largely worked — most objectives met.
• Amgen Inc. / Onyx Pharmaceuticals — 2013 · $10.4B · Largely worked — most objectives met.
• Rallybio Corporation / Avenzo Therapeutics Inc. — 2026 · $300M · Largely worked — most objectives met.
• GSK plc / IDRx Inc. — 2025 · $1.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Mirati Therapeutics — 2023 · $4.8B · Largely worked — most objectives met.
• Servier / Symphogen A/S — 2006 · Largely worked — most objectives met.
• Merck & Co. Inc. / Harpoon Therapeutics — 2024 · $680M · Largely worked — most objectives met.
• AstraZeneca PLC / Gracell Biotechnologies — 2023 · $1.2B · Largely worked — most objectives met.
• Roche Holding AG / mtm laboratories AG — 2011 · $269M · Largely worked — most objectives met.
• Celgene Corporation / Abraxis BioScience Inc. — 2010 · $2.9B · Largely worked — most objectives met.
• Eli Lilly and Company / Scorpion Therapeutics — 2025 · $2.5B · Largely worked — most objectives met.
• AstraZeneca PLC / Fusion Pharmaceuticals Inc. — 2024 · $2.4B · Largely worked — most objectives met.
• Genmab A/S / ProfoundBio Inc. — 2024 · $1.8B · Largely worked — most objectives met.
• Cephalon Inc. / Anesta Corp. — 2000 · $444M · Largely worked — most objectives met.
• Novartis AG / Myricx Bio Ltd. — 2026 · $1.5B · Largely worked — most objectives met.
• Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. — 2026 · $4.0B · Largely worked — most objectives met.
• Pfizer Inc. / 3SBio Inc. — 2025 · $6.0B · Largely worked — most objectives met.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2020 · $6.0B · Largely worked — most objectives met.
• Merck & Co. Inc. / VelosBio Inc. — 2020 · $2.8B · Largely worked — most objectives met.
• Daiichi Sankyo Company, Limited / Ambit Biosciences — 2006 · $410M · Largely worked — most objectives met.
• Remix Therapeutics, Inc. / Passage Bio, Inc. — 2026 · $226M · Largely worked — most objectives met.
• GSK plc / Duality Biologics (Suzhou) Co. Ltd. — 2024 · $975M · Largely worked — most objectives met.
• Merck & Co. Inc. / Kelun-Biotech Biopharmaceuticals Co. Ltd. — 2022 · $936M · Largely worked — most objectives met.
• Mylan Inc. / Bioniche Pharma Holdings Limited — 2010 · $550M · Largely worked — most objectives met.
• AbbVie Inc. / EvolveImmune Therapeutics Inc. — 2024 · $1.5B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Firefly Bio, Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Genentech, Inc. (Roche Group) / Astex Pharmaceuticals — 2026 · $490M · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / ArQule Inc. — 2019 · $2.7B · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson / Ambrx Biopharma Inc. — 2024 · $2.0B · Mixed — partial payoff, real shortfalls.
• Scancell Holdings plc / Neuphoria Therapeutics Inc. — 2026 · $25M · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc. — 2020 · $475M · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / Merck KGaA — 2014 · $2.9B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Absci Corporation — 2023 · $247M · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / TeneoTwo Inc. — 2022 · $1.3B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Innate Pharma SA — 2018 · $1.3B · Mixed — partial payoff, real shortfalls.
• Celgene Corporation / Impact Biomedicines — 2018 · $7.0B · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Ltd. / Tesaro Inc. — 2017 · $340M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Seragon Pharmaceuticals, Inc. — 2014 · $1.7B · Mixed — partial payoff, real shortfalls.
• Orion Corporation / Shilpa Biologicals Private Limited — 2026 · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / CStone Pharmaceuticals — 2020 · $780M · Mixed — partial payoff, real shortfalls.
• Daiichi Sankyo Company, Limited / Plexxikon Inc. — 2011 · $935M · Mixed — partial payoff, real shortfalls.
• Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. — 2026 · $848M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Flatiron Health — 2018 · $1.9B · Mixed — partial payoff, real shortfalls.
• Immunome Inc. / Morphimmune Inc. — 2023 · $125M · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Seagen Inc. — 2019 · $4.2B · Mixed — partial payoff, real shortfalls.
• Otsuka Pharmaceutical / Astex Pharmaceuticals — 2013 · $886M · Mixed — partial payoff, real shortfalls.
• Otsuka Pharmaceutical / Astex Therapeutics — 2013 · $886M · Mixed — partial payoff, real shortfalls.
• Gilead Sciences Inc. / Arcus Biosciences, Inc. — 2020 · $5.0B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Definiens AG — 2014 · $150M · Mixed — partial payoff, real shortfalls.
• Cephalon Inc. / CIMA Labs Inc. — 2004 · $515M · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Eisai Co., Ltd. — 2021 · $3.1B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Agenus Inc. — 2017 · $1.6B · Mixed — partial payoff, real shortfalls.
• Bayer AG / Algeta ASA — 2002 · $2.9B · Mixed — partial payoff, real shortfalls.
• Kyowa Hakko Kirin Co., Ltd. / ProStrakan Group plc — 2011 · $474M · Underwhelmed — fell short of the thesis.
• Novartis AG / BeiGene Ltd. — 2021 · $2.2B · Underwhelmed — fell short of the thesis.
• Bayer AG / Algeta ASA — 2013 · $2.9B · Underwhelmed — fell short of the thesis.
• Amgen Inc. / BioVex Group, Inc. — 2011 · $1.0B · Underwhelmed — fell short of the thesis.
• Novartis AG / MorphoSys AG — 2024 · $2.9B · Underwhelmed — fell short of the thesis.
• Illumina, Inc. / GRAIL, Inc. — 2020 · $8.0B · Underwhelmed — fell short of the thesis.
• Hologic, Inc. / Third Wave Technologies, Inc. — 2008 · $580M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Blueprint Medicines Corporation — 2020 · $1.7B · Underwhelmed — fell short of the thesis.
• Incyte Corporation / Merus N.V. — 2017 · $3.0B · Underwhelmed — fell short of the thesis.
• Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation — 2000 · $250M · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / OSI Pharmaceuticals — 2010 · $4.0B · Underwhelmed — fell short of the thesis.
• Agilent Technologies Inc. / Resolution Bioscience Inc. — 2021 · $695M · Underwhelmed — fell short of the thesis.
• Novartis AG / Agenus Inc. — 2017 · $2.6B · Underwhelmed — fell short of the thesis.
• Sorrento Therapeutics Inc. / Concortis Biosystems Corp. — 2013 · $11M · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Spirogen Limited — 2013 · $440M · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Seagen Inc. — 2020 · $4.2B · Did not work — the deal failed to deliver.
• GlaxoSmithKline plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• GSK plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / IFM Therapeutics, LLC — 2017 · $2.3B · Did not work — the deal failed to deliver.
• Celgene Corporation / Jounce Therapeutics Inc. — 2016 · $2.7B · Did not work — the deal failed to deliver.
• GlaxoSmithKline plc / iTeos Therapeutics S.A. — 2021 · $2.1B · Did not work — the deal failed to deliver.
• Boehringer Ingelheim GmbH / NBE Therapeutics — 2020 · $1.5B · Did not work — the deal failed to deliver.
• Mereo BioPharma Group plc / OncoMed Pharmaceuticals, Inc. — 2018 · $57M · Did not work — the deal failed to deliver.
• Roche Holding AG / Tusk Therapeutics — 2018 · $759M · Did not work — the deal failed to deliver.
• AbbVie Inc. / I-Mab — 2020 · $2.9B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Nektar Therapeutics — 2018 · $3.6B · Did not work — the deal failed to deliver.
• Novartis AG / CoStim Pharmaceuticals, Inc. — 2014 · Did not work — the deal failed to deliver.
• AbbVie Inc. / argenx SE — 2016 · $685M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cormorant Pharmaceuticals AB — 2016 · $520M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Flexus Biosciences, Inc. — 2015 · $1.2B · Did not work — the deal failed to deliver.
• Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc. — 2012 · $2.6B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / IOmet Pharma Ltd. — 2016 · $400M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Five Prime Therapeutics — 2014 · Did not work — the deal failed to deliver.
• Pfizer Inc. / Trillium Therapeutics Inc. — 2021 · $2.3B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Cell Design Labs, Inc. — 2017 · $567M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Amplimmune Inc. — 2013 · $500M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Forty Seven Inc. — 2020 · $4.9B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / cCAM Biotherapeutics Ltd. — 2015 · $605M · Did not work — the deal failed to deliver.
• Adaptimmune Therapeutics plc / GlaxoSmithKline plc — 2016 · $500M · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx Inc. — 2012 · $5.8B · Did not work — the deal failed to deliver.
• Sanofi SA / Synthorx Inc. — 2019 · $2.5B · Did not work — the deal failed to deliver.
• Eli Lilly and Company / ARMO BioSciences Inc. — 2018 · $1.6B · Did not work — the deal failed to deliver.
• Celgene Corporation / OncoMed Pharmaceuticals, Inc. — 2013 · $3.3B · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx Inc. — 2016 · $9.8B · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Pinetree Therapeutics, Inc. — 2026 · $500M
• Roche Holding AG / SAGA Diagnostics AB — 2026 · $595M
• MacroGenics, Inc. / Sagard Healthcare Partners — 2026 · $80M
• BeOne Medicines Ltd. / Huahui Health Ltd. — 2026 · $2.0B
• Sensei Biotherapeutics, Inc. / Faeth Therapeutics — 2026
• BCM Europe AG / OSR Holdings, Inc. — 2026 · $815M
• Pharmanovia / Impact Therapeutics, Inc. — 2026
• Bristol-Myers Squibb Company / Janux Therapeutics — 2026 · $850M
• Phoenix Asia Holdings Limited / ACEA Pharma, Inc. (subsidiary of ACEA Therapeutics / Scilex Holding Company) — 2026 · $1.0B
• Whitehawk Therapeutics, Inc. / Hangzhou DAC Biotech Co., Ltd. — 2026
• Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited — 2026 · $2.1B
• Gilead Sciences Inc. / Arcellx, Inc. — 2026 · $7.8B
• Pathos AI, Inc. / DeuterOncology N.V. — 2026
• Takeda Pharmaceutical Company Ltd. / Iambic Therapeutics, Inc. — 2026 · $1.7B
• Roche Holding AG / PathAI, Inc. — 2026 · $1.1B
• Asahi Kasei Life Science Corporation / The Noguchi Institute — 2026
• Context Therapeutics Inc. / BioAtla, Inc. — 2026 · $6M
• Actimed Therapeutics Ltd / Faraday Pharmaceuticals, Inc. — 2026
• Chugai Pharmaceutical Co. Ltd. / Araris Biotech AG — 2026 · $780M
• Gilead Sciences Inc. / Tubulis GmbH — 2026 · $5.0B
• Rigel Pharmaceuticals, Inc. / Arvinas, Inc. / Pfizer Inc. — 2026 · $405M
• Eli Lilly and Company / CrossBridge Bio, Inc. — 2026 · $300M
• Aptevo Therapeutics Inc. / Niowave, Inc. — 2026
• Novartis AG / Pikavation Therapeutics, Inc. — 2026 · $3.0B
• AbbVie Inc. / Kestrel Therapeutics, Inc. — 2026 · $1.4B
• Bristol-Myers Squibb Company / BioNTech SE — 2025 · $11.1B
• Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc. — 2025 · $780M
• Sino Biopharmaceutical Ltd. / LaNova Medicines Ltd. — 2025 · $951M
• Relmada Therapeutics, Inc. / Trigone Pharma Ltd. — 2025
• Debiopharm / Repare Therapeutics Inc. — 2025 · $267M
• Glenmark Specialty S.A. / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2025 · $1.1B
• Boehringer Ingelheim International GmbH / AimedBio Inc. — 2025 · $991M
• Laboratory Corporation of America Holdings / OPKO Health, Inc. — 2025 · $225M
• Genmab A/S / Merus N.V. — 2025 · $8.0B
• BioNTech SE / CureVac N.V. — 2025 · $1.2B
• F. Hoffmann-La Roche AG / Hansoh Pharmaceutical Group Co. Ltd. — 2025 · $1.5B
• Bristol-Myers Squibb Company / Philochem AG — 2025 · $1.4B
• Kite Pharma, Inc. / Pregene (ShenZhen) Biotechnology Co., Ltd. — 2025 · $1.6B
• AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. — 2025 · $2.0B
• US WorldMeds, LLC / Adaptimmune Therapeutics plc — 2025 · $85M
• Jazz Pharmaceuticals PLC / Chimerix, Inc. — 2025 · $935M
• Johnson & Johnson / Halda Therapeutics, Inc. — 2025 · $3.0B
• Ipsen S.A. / ImCheck Therapeutics SAS — 2025
• Merck & Co. Inc. / LaNova Medicines Ltd. — 2024 · $3.3B
• Eli Lilly and Company / Radionetics Oncology Inc. — 2024 · $1.1B
• Novartis AG / Mariana Oncology Inc. — 2024 · $1.8B
• Pfizer Inc. / Triana Biomedicines Inc. — 2024 · $1.5B
• Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. — 2024 · $850M
• BioNTech SE / Biotheus Inc. (Pumai Biotechnology) — 2024 · $950M
• Avenzo Therapeutics Inc. / VelaVigo Bio Inc. — 2024 · $800M
• Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG — 2023 · $508M
• Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — 2023 · $9.5B
• BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. — 2023 · $1.7B
• Takeda Pharmaceutical Company Ltd. / HUTCHMED (China) Limited — 2023 · $1.1B
• Bristol-Myers Squibb Company / Tubulis GmbH — 2023 · $1.0B
• Eli Lilly and Company / Mablink Bioscience SAS — 2023 · $250M
• Pfizer Inc. / Nona Biosciences (Harbour BioMed subsidiary) — 2023 · $1.1B
• Bristol-Myers Squibb Company / Immatics N.V. — 2022 · $770M
• Sanofi SA / Innate Pharma SA — 2022 · $1.4B
• Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) — 2022 · $1.1B
• Merck & Co. Inc. / Moderna Inc. (mRNA-4157/V940 option exercise) — 2022 · $250M
• Sumitomo Pharma / Sumitovant Biopharma / Myovant Sciences Ltd. — 2022 · $1.7B
• Sanofi SA / Adagene Inc. — 2022 · $2.5B
• AstraZeneca PLC / Neogene Therapeutics B.V. — 2022 · $320M
• Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. — 2021
• Amgen Inc. / Teneobio, Inc. — 2021 · $2.5B
• Eli Lilly and Company / Foghorn Therapeutics Inc. — 2021 · $1.7B
• Eli Lilly and Company / Kumquat Biosciences, Inc. — 2021 · $2.1B
• Roche Holding AG / Adaptimmune Therapeutics plc — 2021 · $3.3B
• Sanofi SA / Tidal Therapeutics, Inc. — 2021 · $470M
• Takeda Pharmaceutical Company Ltd. / GammaDelta Therapeutics Limited — 2021 · $350M
• Merck KGaA / Debiopharm — 2021 · $1.1B
• BioNTech SE / Kite Pharma (Gilead Sciences) — 2021 · $250M
• Illumina, Inc. / GRAIL, Inc. — 2021 · $7.1B
• Genmab A/S / Bolt Biotherapeutics, Inc. — 2021 · $880M
• Eli Lilly and Company / Merus N.V. — 2021 · $1.7B
• Bristol-Myers Squibb Company / Agenus Inc. — 2021 · $1.6B
• Bristol-Myers Squibb Company / Immatics N.V. — 2021 · $920M
• Bristol-Myers Squibb Company / Repare Therapeutics Inc. — 2020 · $3.1B
• Servier / Symphogen A/S — 2020
• Merck & Co. Inc. / Taiho Pharmaceutical / Astex Pharmaceuticals — 2020 · $2.5B
• Pfizer Inc. / Myovant Sciences Ltd. — 2020 · $4.2B
• Boehringer Ingelheim GmbH / NBE-Therapeutics AG — 2020 · $1.4B
• Roche Holding AG / Bicycle Therapeutics plc — 2020 · $1.7B
• Astellas Pharma Inc. / Potenza Therapeutics, Inc. — 2019 · $405M
• Boehringer Ingelheim GmbH / AMAL Therapeutics SA — 2019 · $366M
• Eli Lilly and Company / AurKa Pharma Inc. — 2019 · $575M
• Johnson & Johnson / Auris Health, Inc. — 2019 · $5.8B
• Roche Holding AG / Adaptive Biotechnologies Corp. — 2019 · $2.3B
• Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) — 2019 · $3.0B
• Roche Holding AG / Xencor, Inc. — 2019 · $1.6B
• NJCTTQ (Nanjing CTTQ Pharma) / Abpro Corporation — 2019 · $4.0B
• Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc. — 2017 · $1.9B
• Servier / Pieris Pharmaceuticals, Inc. — 2017 · $1.7B
• Bayer AG / Loxo Oncology, Inc. — 2017 · $1.6B
• Merck KGaA / Vertex Pharmaceuticals Incorporated — 2017 · $1.2B
• Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. — 2016 · $910M
• Hanmi Pharmaceutical Co. Ltd. / Boehringer Ingelheim GmbH — 2016 · $730M
• Novartis AG / Aduro Biotech, Inc. (STING pathway program) — 2015 · $750M
• Bristol-Myers Squibb Company / Bavarian Nordic A/S (PROSTVAC program) — 2015 · $975M
• Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. (CSF1R antibody program) — 2015 · $1.7B
• Boehringer Ingelheim International GmbH / Hanmi Pharmaceutical Co., Ltd. (HM61713 program) — 2015 · $730M
• Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. — 2014
• Eli Lilly and Company / Immunocore Limited — 2014 · $365M
• Celgene Corporation / Sutro Biopharma, Inc. — 2014 · $185M
• Merck & Co. Inc. / Ablynx NV — 2014 · $2.3B
• Bristol-Myers Squibb Company / CytomX Therapeutics, Inc. — 2014 · $1.2B
• Celgene Corporation / Forma Therapeutics Holdings Inc. — 2013 · $200M
• Merck KGaA / Threshold Pharmaceuticals, Inc. — 2012 · $550M
• Merck & Co. Inc. / Endocyte, Inc. — 2012 · $1.0B
• Bayer AG / Onyx Pharmaceuticals — 2011 · $160M
• Roche Holding AG / Plexxikon Inc. — 2009 · $335M

← Deal Library  ·  Interactive search  ·  How we score deals